PL1982708T3 - Środek terapeutyczny w przypadku nieswoistego zapalenia jelit zawierający pochodną 2-amino-1.3-propanodiolu jako substancję czynną oraz sposób leczenia nieswoistego zapalenia jelit - Google Patents

Środek terapeutyczny w przypadku nieswoistego zapalenia jelit zawierający pochodną 2-amino-1.3-propanodiolu jako substancję czynną oraz sposób leczenia nieswoistego zapalenia jelit

Info

Publication number
PL1982708T3
PL1982708T3 PL07713815T PL07713815T PL1982708T3 PL 1982708 T3 PL1982708 T3 PL 1982708T3 PL 07713815 T PL07713815 T PL 07713815T PL 07713815 T PL07713815 T PL 07713815T PL 1982708 T3 PL1982708 T3 PL 1982708T3
Authority
PL
Poland
Prior art keywords
inflammatory bowel
bowel disease
propanaediol
derivative
amino
Prior art date
Application number
PL07713815T
Other languages
English (en)
Inventor
Ryotaro Kojima
Koichi Nakamaru
Tokutarou Yasue
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1982708(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of PL1982708T3 publication Critical patent/PL1982708T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07713815T 2006-02-06 2007-02-05 Środek terapeutyczny w przypadku nieswoistego zapalenia jelit zawierający pochodną 2-amino-1.3-propanodiolu jako substancję czynną oraz sposób leczenia nieswoistego zapalenia jelit PL1982708T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006027883 2006-02-06
EP07713815.4A EP1982708B1 (en) 2006-02-06 2007-02-05 Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
PCT/JP2007/051887 WO2007091501A1 (ja) 2006-02-06 2007-02-05 ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする炎症性腸疾患治療剤又は炎症性腸疾患の治療方法

Publications (1)

Publication Number Publication Date
PL1982708T3 true PL1982708T3 (pl) 2015-03-31

Family

ID=38345101

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07713815T PL1982708T3 (pl) 2006-02-06 2007-02-05 Środek terapeutyczny w przypadku nieswoistego zapalenia jelit zawierający pochodną 2-amino-1.3-propanodiolu jako substancję czynną oraz sposób leczenia nieswoistego zapalenia jelit

Country Status (29)

Country Link
US (1) US8318811B2 (pl)
EP (2) EP1982708B1 (pl)
JP (1) JP5042042B2 (pl)
KR (1) KR101334153B1 (pl)
CN (1) CN101378743B (pl)
AU (1) AU2007213194B9 (pl)
BR (1) BRPI0706971A2 (pl)
CA (1) CA2641546C (pl)
CY (1) CY1116112T1 (pl)
DK (1) DK1982708T3 (pl)
EC (1) ECSP088662A (pl)
ES (1) ES2524056T3 (pl)
GT (1) GT200800148A (pl)
HR (1) HRP20080421B1 (pl)
IL (1) IL192150A (pl)
MA (1) MA31338B1 (pl)
MX (1) MX2008008872A (pl)
MY (1) MY151193A (pl)
NO (1) NO20082708L (pl)
NZ (1) NZ568907A (pl)
PL (1) PL1982708T3 (pl)
PT (1) PT1982708E (pl)
RU (1) RU2428976C2 (pl)
SG (1) SG169370A1 (pl)
SI (1) SI1982708T1 (pl)
TN (1) TNSN08246A1 (pl)
TW (1) TWI389683B (pl)
WO (1) WO2007091501A1 (pl)
ZA (1) ZA200806199B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1932522T3 (pl) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (en) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP5140593B2 (ja) 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CA2724592A1 (en) * 2008-05-20 2009-11-26 Kyorin Pharmaceutical Co., Ltd. Agent for maintenance of induced remission
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
WO2010051030A1 (en) * 2008-10-30 2010-05-06 Biogen Idec Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
KR101787543B1 (ko) 2014-08-22 2017-10-19 샘표식품 주식회사 발효배양 산삼을 포함하는 항염증 조성물
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
IL280451B2 (en) 2018-07-27 2025-10-01 Priothera Ltd A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP1092435B1 (en) 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2001098301A1 (en) 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
JP2004529100A (ja) 2001-01-30 2004-09-24 ユニバーシティ オブ バージニア パテント ファウンデーション スフィンゴシン−１−ホスフェートレセプターのアゴニストおよびアンタゴニスト
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
JP4318921B2 (ja) 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
CA2442178A1 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2316613T3 (es) 2001-05-10 2009-04-16 Ono Pharmaceutical Co., Ltd. Derivados de acido crboxilico y composiciones farmaceuticas que contienen los mismos como ingrediente activo.
US20040138462A1 (en) 2001-05-24 2004-07-15 Minoru Sakurai Aminoalcohol derivatives
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
DE60235900D1 (de) * 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003074008A2 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
JP2005533058A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
JPWO2004002531A1 (ja) 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CN100516024C (zh) 2002-09-13 2009-07-22 诺瓦提斯公司 氨基-丙醇衍生物
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
EP1575576A2 (en) 2002-09-24 2005-09-21 Novartis AG Organic compounds
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
DE60335827D1 (de) 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
PL378134A1 (pl) 2003-02-11 2006-03-06 Irm Llc Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
BRPI0407658A (pt) 2003-02-18 2006-02-21 Kyorin Seiyaku Kk derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico
PE20130200A1 (es) * 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
CN1777575B (zh) 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
MXPA05011597A (es) 2003-04-30 2005-12-15 Novartis Ag Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
MXPA05012459A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
WO2005014603A1 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Phosphinane compounds with immunomodulating activity
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
US7718704B2 (en) 2004-02-24 2010-05-18 Irm Llc Immunosuppressant compounds and compositions
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
NZ550533A (en) * 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
AU2005237254B2 (en) 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
GB0411929D0 (en) 2004-05-27 2004-06-30 Novartis Ag Organic compounds
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
WO2006041015A1 (ja) 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006063033A2 (en) 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
ES2529724T3 (es) 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
PL1932522T3 (pl) 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
US8546452B2 (en) 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ZA200900316B (en) 2006-07-25 2010-05-26 Alcon Res Ltd Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders
US7877152B2 (en) 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
IL192150A (en) 2015-04-30
SI1982708T1 (sl) 2015-01-30
EP1982708A4 (en) 2010-03-17
NO20082708L (no) 2008-09-02
CA2641546C (en) 2013-12-24
HRP20080421B1 (hr) 2015-07-17
ZA200806199B (en) 2009-04-29
ECSP088662A (es) 2008-09-29
IL192150A0 (en) 2008-12-29
US8318811B2 (en) 2012-11-27
PT1982708E (pt) 2014-12-23
GT200800148A (es) 2008-10-29
CN101378743A (zh) 2009-03-04
TWI389683B (zh) 2013-03-21
KR20080096650A (ko) 2008-10-31
EP1982708B1 (en) 2014-11-05
CA2641546A1 (en) 2007-08-16
JP5042042B2 (ja) 2012-10-03
RU2428976C2 (ru) 2011-09-20
EP1982708A1 (en) 2008-10-22
AU2007213194A1 (en) 2007-08-16
BRPI0706971A2 (pt) 2011-09-27
RU2008135264A (ru) 2010-03-20
MY151193A (en) 2014-04-30
EP2520291A1 (en) 2012-11-07
TW200806281A (en) 2008-02-01
ES2524056T3 (es) 2014-12-03
MX2008008872A (es) 2008-10-23
JPWO2007091501A1 (ja) 2009-07-02
US20090137685A1 (en) 2009-05-28
HRP20080421A2 (en) 2008-12-31
AU2007213194B2 (en) 2013-03-14
TNSN08246A1 (en) 2009-10-30
CY1116112T1 (el) 2017-02-08
HK1126119A1 (en) 2009-08-28
KR101334153B1 (ko) 2013-11-28
AU2007213194B9 (en) 2013-05-16
CN101378743B (zh) 2014-05-28
WO2007091501A1 (ja) 2007-08-16
NZ568907A (en) 2011-08-26
DK1982708T3 (en) 2014-12-01
SG169370A1 (en) 2011-03-30
MA31338B1 (fr) 2010-05-03

Similar Documents

Publication Publication Date Title
ZA200806199B (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease
IL264796B (en) History of 6,23-metabolized bile acid, pharmaceutical preparations acceptable in a pharmacy and compounds for use in a method for treating or preventing a disease
IL264361B (en) Compositions and methods for treating collagen-mediated diseases
IL209282A (en) History of n-pipridine-3-yl-2-benzimidazole carboxamide and drugs containing it for the treatment of cardiovascular disease
EP1804813A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
PL2371853T3 (pl) Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna, zastosowanie pochodnej insuliny lub jej farmaceutycznie dopuszczalnej soli oraz sposób leczenia
PL2001466T3 (pl) Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
IL176960A0 (en) Compositions and methods of treatment for inflammatory diseases
IL197934A (en) History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
EP1920770A4 (en) THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
PT2056863T (pt) Tratamento de doenças oculares
IL201418A0 (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
BRPI0617077A2 (pt) Agente terapêutico para tratamento de doenças do fígado contendo 2-amina-1, 3-propanediol derivativo como ingrediente ativo, e método para tratamento de doenças do fígado
PT1828151E (pt) Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
ZA200704684B (en) Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
IL193683A0 (en) Methods and compositions for treatment of diastolic heart failure
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
PL1876175T3 (pl) Środek terapeutyczny do leczenia chorób rogówki
GB0501129D0 (en) Method of treatment by administration of RNA
GB0705001D0 (en) Composition and method for treatment of drug dependence and disease